Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of ZOSTAVAX at Expiry Potency
NCT00681031Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- May 2008
- Primary completion
- Jun 2008
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 4, open-label, single-arm trial of varicella virus vaccine live in herpes zoster (HZ), sponsored by Merck & Co. Primary endpoint: Geometric Mean Titre of Varicella Antibodies. Started May 2008; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT00681031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681031.